mapping the effectiveness and risks of glp 1 GLP-1 receptor agonists mapping the effectiveness and risks
Description
Doug Long, IQVIAs VP of Industry Relations, and Scott Biggs, the companys Director of Supplier Services, teamed in the presentation taking on the landscape of issues shaping the U.S
But their side effects often drive people to stop using them over the long term.
Learn about potential interactions, essential safety considerations, and expert guidance for combining these medications.
About 19% of large employers now cover GLP-1 drugs used primarily for weight
